[The assessment of the state of the blood lipid spectrum, hemostasis, hormonal homeostasis and hemodynamics in the early diagnosis and drug correction of the cardiovascular changes in prostatic cancer patients undergoing estrogen therapy].
A complex of investigation was performed in 30 males with newly diagnosed prostatic cancer (stages T2NOMO-T3NO-1MO) before treatment with estrogens, 2-3 months and 1 year after its start. The complex included evaluation of blood lipid spectrum (HDL, LDL, VLDL, triglycerides), hemostasis (coagulation, platelet aggregation, fibrinolysis), hormonal profile (blood hydrocortisone, aldosterone, testosterone, estradiol, STH, FSH, LH, prolactin, plasma renin activity), central and intracardiac hemodynamics, ECG. 66 healthy men of advanced age served control. It was found that estrogen therapy affected blood lipid metabolism, leading to impairment of physiological correlation between HDL and triglycerides, increased blood levels of VLDL and triglycerides. Long-term estrogen treatment brought about enhancement of hemocoagulation and platelet aggregation. Hormonal shifts involved hyperprolactinemia, hypersomatotropism, hypercorticism, aldosterone hypersecretion, proportional androgens-estrogens alterations. Hormonal abnormalities produce side effects in estrogen-treated CHD and hypertonic patients: negative ECG readings indicative of deteriorated coronary circulation and hypertensive episodes, central hemodynamic disorders, respectively. In view of possible cardiovascular damage related to estrogen therapy, a differentiated approach is proposed which would allow a long-term estrogen treatment free of relevant complications.
Portnoĭ
A S
AS
Begunov
A V
AV
D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D045166:Estradiol Congeners / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006706:Homeostasis / Q000187:drug effects*; D006728:Hormones / Q000097:blood*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors
D045166:Estradiol Congeners; D006728:Hormones; D008055:Lipids
Otsenka sostoianiia lipidnogo spektra krovi, gemostaza, gormonal'nogo gomeostaza i gemodinamiki v ranneĭ diagnostike i medikamentoznoĭ korrektsii serdechno-sosudistykh izmeneniĭ u bol'nykh rakom predstatel'noĭ zhelezy pri éstrogenoterapii.